Current Appointments & Affiliations
Associate Professor of Medicine
·
2024 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Member of the Duke Cancer Institute
·
2016 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase.
Journal Article Hematology · December 2025 INTRODUCTION: Chronic myeloid leukemia in the chronic phase (CML-CP) has undergone therapeutic transformation with the advent of BCR::ABL1 tyrosine kinase inhibitors (TKIs), improving 10-year survival rates from 20% to ∼90%. These outcomes place increasing ... Full text Link to item CiteBeta-Arrestin 1 Deficiency Enhances Host Anti-Myeloma Immunity Through T Cell Activation and Checkpoint Modulation.
Journal Article Int J Mol Sci · November 27, 2025 Beta-arrestin 1 (ARRB1) is a multifunctional adaptor protein that regulates diverse signaling pathways beyond its canonical role in G-protein-coupled receptor desensitization. While ARRB1 has been implicated in cancer progression, its role in modulating ho ... Full text Open Access Link to item CiteMastocytosis: Part I: Pathogenesis, Clinical Presentation and Classification.
Journal Article J Am Acad Dermatol · June 19, 2025 Mast cells are tissue-resident immune cells which secrete numerous and varied immune mediators in response to a myriad of activation pathways and play an important physiological function in immunity, homeostasis, tissue repair, and nervous system regulatio ... Full text Link to item CiteRecent Grants
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Clinical Study to Assess Efficacy and Safety of Ropeginterferon alfa-2b (P1101) in Adult Patients with Pre-fibrotic/Early Primary Myelofibrosis or Overt Primary Myelofibrosis at Low
Clinical TrialPrincipal Investigator · Awarded by PharmaEssentia Corporation · 2025 - 2030A Phase 2a, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DISC-3405 in Participants with Polycythemia Vera (PV
Clinical TrialPrincipal Investigator · Awarded by Disc Medicine Inc. · 2025 - 2030A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study
Clinical TrialPrincipal Investigator · Awarded by Merck Sharp & Dohme LLC. · 2025 - 2030View All Grants
Education
University of North Dakota, School of Medicine and Health Sciences ·
2008
M.D.